NASDAQ:IMRX Immuneering (IMRX) Stock Price, News & Analysis $1.24 +0.01 (+0.81%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.20▼$1.3050-Day Range$1.09▼$1.6952-Week Range$1.05▼$10.99Volume65,135 shsAverage Volume432,397 shsMarket Capitalization$36.77 millionP/E RatioN/ADividend YieldN/APrice Target$13.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Immuneering alerts: Email Address Immuneering MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside988.7% Upside$13.50 Price TargetShort InterestBearish13.71% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.93) to ($2.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.69 out of 5 starsMedical Sector479th out of 936 stocksPharmaceutical Preparations Industry219th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingImmuneering has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageImmuneering has only been the subject of 1 research reports in the past 90 days.Read more about Immuneering's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.71% of the float of Immuneering has been sold short.Short Interest Ratio / Days to CoverImmuneering has a short interest ratio ("days to cover") of 10.4, which indicates bearish sentiment.Change versus previous monthShort interest in Immuneering has recently decreased by 17.24%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldImmuneering does not currently pay a dividend.Dividend GrowthImmuneering does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IMRX. Previous Next 3.3 News and Social Media Coverage News SentimentImmuneering has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Immuneering this week, compared to 2 articles on an average week.MarketBeat Follows4 people have added Immuneering to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Immuneering insiders have not sold or bought any company stock.Percentage Held by Insiders25.00% of the stock of Immuneering is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions67.65% of the stock of Immuneering is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Immuneering's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Immuneering are expected to decrease in the coming year, from ($1.93) to ($2.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Immuneering is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Immuneering is -0.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmuneering has a P/B Ratio of 0.40. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Immuneering's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Immuneering Stock (NASDAQ:IMRX)Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Read More IMRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMRX Stock News HeadlinesJuly 21, 2024 | americanbankingnews.comAnalysts Set Immuneering Co. (NASDAQ:IMRX) PT at $13.50July 9, 2024 | 247wallst.com3 Penny Stocks With 735% Average Upside, According to Wall StreetJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 29, 2024 | globenewswire.comImmuneering to Present at the Jefferies Global Healthcare ConferenceMay 19, 2024 | morningstar.comImmuneering Corp Class A IMRXMay 17, 2024 | finanznachrichten.deUSA News Group: Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer TreatmentMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Immuneering with $8 Price Target Amidst Promising Pipeline and Upcoming Data EventsMay 8, 2024 | markets.businessinsider.comBuy Rating Maintained for Immuneering Amid Promising Clinical Pipeline DevelopmentsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 7, 2024 | globenewswire.comImmuneering Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 7, 2024 | finance.yahoo.comWe Think Immuneering (NASDAQ:IMRX) Needs To Drive Business Growth CarefullyMay 6, 2024 | globenewswire.comImmuneering Recognizes Melanoma Awareness MonthMay 2, 2024 | markets.businessinsider.comBuy Rating Affirmed: Immuneering’s Lead Asset IMM-1-104 Shows Promise Despite Market SkepticismApril 17, 2024 | msn.comImmuneering (IMRX) Price Target Decreased by 11.43% to 13.55April 11, 2024 | investing.comImmuneering advances pancreatic cancer treatment trialApril 9, 2024 | finanznachrichten.deImmuneering Corporation: IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 9, 2024 | globenewswire.comIMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer ModelsApril 3, 2024 | globenewswire.comImmuneering to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceSee More Headlines Receive IMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immuneering and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IMRX CUSIPN/A CIK1790340 Webwww.immuneering.com Phone617-500-8080FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$13.50 High Stock Price Target$25.00 Low Stock Price Target$3.00 Potential Upside/Downside+988.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-53,470,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-55.79% Return on Assets-50.47% Debt Debt-to-Equity RatioN/A Current Ratio14.38 Quick Ratio14.38 Sales & Book Value Annual Sales$320,000.00 Price / Sales114.91 Cash FlowN/A Price / Cash FlowN/A Book Value$3.09 per share Price / Book0.40Miscellaneous Outstanding Shares29,653,000Free Float22,240,000Market Cap$36.77 million OptionableNot Optionable Beta-0.61 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Benjamin J. Zeskind M.B.A. (Age 41)Ph.D., Co-Founder, President, CEO & Director Comp: $935.09kMr. Robert J. Carpenter M.B.A. (Age 78)M.S., Co-Founder & Chair Emeritus Comp: $75.36kDr. Brett M. Hall Ph.D. (Age 55)Chief Scientific Officer Comp: $905.41kMr. Harold E. Brakewood (Age 58)Chief Business Officer Comp: $579.77kMs. Mallory Morales CPA (Age 40)Principal Financial & Accounting Officer, Chief Accounting Officer and Treasurer Ms. Paula George CPADirector of Accounting & Operations and Assistant Corporate ControllerMr. Michael D. Bookman J.D. (Age 37)Chief Legal Officer & Secretary Ms. Leah R. Neufeld (Age 51)Chief People Officer Dr. Peter King Ph.D.Head of Discovery & VPDr. Praveen Nair Ph.D.Head of Translational Pharmacology & VPMore ExecutivesKey CompetitorsRapid Micro BiosystemsNASDAQ:RPIDIncannex HealthcareNASDAQ:IXHLCorvus PharmaceuticalsNASDAQ:CRVSInventivaNASDAQ:IVAAmylyx PharmaceuticalsNASDAQ:AMLXView All CompetitorsInsiders & InstitutionsPrice T Rowe Associates Inc. MDSold 2,467,834 shares on 5/15/2024Ownership: 3.070%Vanguard Group Inc.Bought 129,851 shares on 5/10/2024Ownership: 4.060%Cormorant Asset Management, LpSold 400,000 sharesTotal: $1.16 M ($2.90/share)Peter FeinbergBought 25,000 shares on 3/22/2024Total: $63,750.00 ($2.55/share)Harold Eugene BrakewoodBought 3,900 shares on 3/22/2024Total: $10,023.00 ($2.57/share)View All Insider TransactionsView All Institutional Transactions IMRX Stock Analysis - Frequently Asked Questions How have IMRX shares performed this year? Immuneering's stock was trading at $7.35 at the beginning of the year. Since then, IMRX shares have decreased by 83.1% and is now trading at $1.24. View the best growth stocks for 2024 here. How were Immuneering's earnings last quarter? Immuneering Co. (NASDAQ:IMRX) released its earnings results on Tuesday, May, 7th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.45) by $0.04. When did Immuneering IPO? Immuneering (IMRX) raised $105 million in an IPO on Friday, July 30th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Jefferies, Cowen and Guggenheim Securities acted as the underwriters for the IPO. How do I buy shares of Immuneering? Shares of IMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IMRX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredFormer Hedge Fund Manager Issues Crash PredictionOur No. 1 stock for the rare "millionaire window" opening NOW According to Wall Street legend Whitney Tilso...Stansberry Research | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
